|
Colorectal Carcinoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
Taken together, these results indicate that metformin suppresses human colorectal cancer growth by inducing apoptosis via ADORA1, which provide evidence the anti-neoplastic effects of metformin in the treatment of human colorectal cancer.
|
27814614 |
2017 |
|
Schizophrenia
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we investigated the contribution of genetic variations of ADORA1 to the pathophysiological mechanisms of Japanese schizophrenia patients.
|
19820430 |
2009 |
|
Sleep Apnea, Obstructive
|
0.210 |
Biomarker
|
disease |
BEFREE |
However, little is known about whether ADORA1 takes part in the course of neuronal cell injury after intermittent hypoxia exposure which was the main pathological characteristic of OSAHS.
|
29380238 |
2018 |
|
Asthma
|
0.130 |
AlteredExpression
|
disease |
BEFREE |
EPI-2010 has been shown to inhibit adenosine A(1) receptor expression and significantly improve allergen-induced airway obstruction and bronchial hyper-responsiveness in animal models of human asthma.
|
11728229 |
2001 |
|
Asthma
|
0.130 |
Biomarker
|
disease |
BEFREE |
Pharmacological approach of translation in asthma includes therapeutic ribozymes and antisense oligonucleotides targeting receptors (adenosine A1 receptor, alpha chain of IL-5 receptor, common beta chain of IL-3/IL-5/GM-CSF receptor), cytokines (IL-4, IL-5, SCF), signal transduction molecules (Syk, Lyn), transcription factors (STAT-6, GATA-3).
|
14754517 |
2004 |
|
Asthma
|
0.130 |
Biomarker
|
disease |
BEFREE |
Potential anti-mRNA drugs in asthma and other allergic disorders may be targeted to cell surface receptors (adenosine A1 receptor, high-affinity receptor Fc-epsilon RI-alpha, cytokine receptors), adhesion molecules and ligands (ICAM-1, VLA-4), ion channels (calcium-dependent chloride channel-1), cytokines and related factors (IL-4, IL-5, IL-13, SCF, TNF-alpha, TGF-beta1), intracellular signal transduction molecules, such as tyrosine-protein kinases (Syk, Lyn, Btk), serine/ threonine-protein kinases (p38 alpha MAPkinase, Raf-1), non-kinase signaling proteins (RasGRP4), and transcription factors involved in Th2 differentiation and allergic inflammation (STAT-6, GATA-3, NF-kappaB).
|
16364194 |
2006 |
|
Caffeine related disorders
|
0.040 |
Biomarker
|
group |
BEFREE |
In light of our previous finding that the analgesic effect of acupuncture is mediated by adenosine A1 receptor activation at the acupuncture point, we here report that in acute and chronic animal pain models, oral intake of caffeine, a potent adenosine receptor antagonist, interferes with acupuncture analgesia, even at a low dose.
|
28611421 |
2017 |
|
Caffeine related disorders
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Administration of escitalopram or fluoxetine followed by caffeine withdrawal caused an increase in this gene expression, whereas administration of escitalopram, but not fluoxetine, on day 15th together with caffeine caused a decrease in Adora1 mRNA level in the Cx.
|
29107002 |
2017 |
|
Caffeine related disorders
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Withdrawal of caffeine after its chronic administration modifies the antidepressant-like activity of atypical antidepressants in mice. Changes in cortical expression of Comt, Slc6a15 and Adora1 genes.
|
29882086 |
2018 |
|
Caffeine related disorders
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Caffeine increased the protein levels of A<sub>1</sub>R without altering ADORA1 mRNA and was devoid of effects on A<sub>2A</sub>R density or ADORA2A mRNA levels.
|
31563462 |
2019 |
|
Diabetes
|
0.030 |
Biomarker
|
disease |
BEFREE |
Expression of the spliced variant (Adora1-Var) was upregulated in the pancreas of 12-week-old NOD versus age-matched NOD.B10 (non-diabetes-susceptible) control mice and was detected in the pancreas of AA(+) patients but not in control subjects or overtly diabetic patients, suggesting that inflammation drives the splicing of Adora1.
|
24264405 |
2013 |
|
Diabetes
|
0.030 |
Biomarker
|
disease |
BEFREE |
This hypothesis has recently been questioned due to the observation that adenosine A(1)-receptor knockout mice, previously shown to lack a functional TGF mechanism, still display a pronounced hyperfiltration when diabetes is induced.
|
20518753 |
2010 |
|
Diabetes
|
0.030 |
Biomarker
|
disease |
BEFREE |
Loss of Deaf1 function leads to reduced peripheral tissue antigen expression in lymph node stromal cells and may contribute to a breakdown in peripheral tolerance, while reduced Adora1 function results in an early intrinsic alpha cell defect that may explain the hyperglucagonemia and resulting beta cell stress observed prior to the onset of diabetes.
|
24682832 |
2014 |
|
Diabetes Mellitus
|
0.030 |
Biomarker
|
group |
BEFREE |
Loss of Deaf1 function leads to reduced peripheral tissue antigen expression in lymph node stromal cells and may contribute to a breakdown in peripheral tolerance, while reduced Adora1 function results in an early intrinsic alpha cell defect that may explain the hyperglucagonemia and resulting beta cell stress observed prior to the onset of diabetes.
|
24682832 |
2014 |
|
Diabetes Mellitus
|
0.030 |
Biomarker
|
group |
BEFREE |
Expression of the spliced variant (Adora1-Var) was upregulated in the pancreas of 12-week-old NOD versus age-matched NOD.B10 (non-diabetes-susceptible) control mice and was detected in the pancreas of AA(+) patients but not in control subjects or overtly diabetic patients, suggesting that inflammation drives the splicing of Adora1.
|
24264405 |
2013 |
|
Diabetes Mellitus
|
0.030 |
Biomarker
|
group |
BEFREE |
This hypothesis has recently been questioned due to the observation that adenosine A(1)-receptor knockout mice, previously shown to lack a functional TGF mechanism, still display a pronounced hyperfiltration when diabetes is induced.
|
20518753 |
2010 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Diminished adenosine A1 receptor expression in pancreatic α-cells may contribute to the pathology of type 1 diabetes.
|
24264405 |
2013 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Here, we describe two genes, Deformed epidermal autoregulatory factor 1 (Deaf1) and Adenosine A1 receptor (Adora1), that are differentially expressed and alternatively spliced in the pancreatic lymph nodes or islets of NOD mice and T1D patients to form dominant-negative non-functional isoforms.
|
24682832 |
2014 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Several lines of experimental evidence suggest that an excess of adenosine A1 receptor activity may contribute to adiposity in NIDDM.
|
10459555 |
1999 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
New pharmacological approaches to NIDDM and obesity have focused on insulin-sensitizing agents (e.g. troglitazone), beta3-AR agonists, anti-lipolytic drugs (e.g. the adenosine A1 receptor agonist GR79236) and selective inhibitors of PKC isoforms (e.g. the inhibitor of PKC-beta LY333531).
|
9493493 |
1998 |
|
Epilepsy
|
0.020 |
Biomarker
|
disease |
BEFREE |
This study assessed expression of adenosine P1 receptors, ADORA1 (adenosine A1 receptor) and ADORA2A (adenosine A2a receptor) and their association with glioma development and epilepsy in glioma patients.
|
27038930 |
2016 |
|
Epilepsy
|
0.020 |
Biomarker
|
disease |
BEFREE |
At the same time, NBTI mimics adenosine to attenuate the epileptiform discharge through adenosine A1 receptor, which might provide a novel therapeutic approach toward the control of epilepsy.
|
28415676 |
2017 |
|
Neuralgia
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These results indicated that the adenosine A1 receptor is involved in EA actions during neuropathic pain through suppressing astrocyte activation as well as TNF-α upregulation of EA, giving enlightenment to the mechanisms of acupuncture analgesia and development of therapeutic targets for neuropathic pain.
|
30570016 |
2018 |
|
Neuralgia
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Downregulation of adenosine and adenosine A1 receptor contributes to neuropathic pain in resiniferatoxin neuropathy.
|
29672450 |
2018 |
|
Seizures
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
To test the susceptibility of MO adora1, MO adora2aa, MO adora2ab, and MO adora2aa + adora2ab animals to seizure, pentylenetetrazole (10 mM) was used as a convulsant agent in larval and adult stages of zebrafish development.
|
29327202 |
2018 |